参考文献/References:
[1] 中华医学会妇产科学分会绝经学组.绝经管理与绝经激素治疗中国指南(2018)[J].中华妇产科杂志,2018,53(11):729-739.DOI:10.3760/cma.j.issn.0529-567x.2018.11.001.
[2] Roberts H,Hickey M.Managing the menopause:an update[J].Maturitas,2016,86:53-58.DOI:10.1016/j.maturitas.2016.01.007.
[3] Harlow SD,Gass M,Hall JE,et al.Executive summary of the stages of reproductive aging workshop + 10:addressing the unfinished agenda of staging reproductive aging[J].J Clin Endocrinol Metab,2012,97(4):1159-1168.DOI:10.1210/jc.2011-3362.
[4] Hall JE.Endocrinology of the menopause[J].Endocrinol Metab Clin North Am,2015,44(3):485-496.DOI:10.1016/j.ecl.2015.05.010.
[5] Avis NE,Crawford SL,Greendale G,et al.Duration of menopausal vasomotor symptoms over the menopause transition[J].JAMA Intern Med,2015,175(4):531-539.DOI:10.1001/jamainternmed.2014.8063.
[6] Ren Y,Zhang M,Liu Y,et al.Association of menopause and type 2 diabetes mellitus[J].Menopause,2019,26(3):325-330.DOI:10.1097/GME.0000000000001200.
[7] de Villiers TJ,Hall JE,Pinkerton JV,et al.Revised global consensus statement on menopausal hormone therapy[J].Maturitas,2016,91:153-155.DOI:10.1016/j.maturitas.2016.06.001.
[8] Zhu D,Chung HF,Dobson AJ,et al.Vasomotor menopausal symptoms and risk of cardiovascular disease:a pooled analysis of six prospective studies[J].Am J Obstet Gynecol,2020,223(6):898.e1-898.e16.DOI:10.1016/j.ajog.2020.06.039.
[9] Lundberg G,Wu P,Wenger N.Menopausal hormone therapy:a comprehensive review[J].Curr Atheroscler Rep,2020,22(8):33.DOI:10.1007/s11883-020-00854-8.
[10] Santoro N,Komi J.Prevalence and impact of vaginal symptoms among postmenopausal women[J].J Sex Med,2009,6(8):2133-2142.DOI:10.1111/j.1743-6109.2009.01335.x.
[11] 彭红发,闫晓楠,徐春琳.绝经激素治疗与骨质疏松症[J].中国实用妇科与产科杂志,2020,36(3):230-233.DOI:10.19538/j.fk2020030112.
[12] Gordon JL,Girdler SS.Hormone replacement therapy in the treatment of perimenopausal depression[J].Curr Psychiatry Rep,2014,16(12):517.DOI:10.1007/s11920-014-0517-1.
[13] Slopien R,Wender-Ozegowska E,Rogowicz-Frontczak A,et al.Menopause and diabetes:EMAS clinical guide[J].Maturitas,2018,117:6-10.DOI:10.1016/j.maturitas.2018.08.009.
[14] Anderson GL,Limacher M,Assaf AR,et al.Effects of conjugated equine estrogen in postmenopausal women with hysterectomy:the Women's Health Initiative randomized controlled trial[J].JAMA,2004,291(14):1701-1712.DOI:10.1001/jama.291.14.1701.
[15] Manson JE,Aragaki AK,Rossouw JE,et al.Menopausal hormone therapy and long-term all-cause and cause-specific mortality:the women's health initiative randomized trials[J].JAMA,2017,318(10):927-938.DOI:10.1001/jama.2017.11217.
[16] Prabakaran S,Schwartz A,Lundberg G.Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy:risks,benefits,and current guidelines for use[J].Ther Adv Endocrinol Metab,2021,12:20420188211013917.DOI:10.1177/20420188211013917.
[17] Collaborative Group on Hormonal Factors in Breast Cancer.Type and timing of menopausal hormone therapy and breast cancer risk:individual participant meta-analysis of the worldwide epidemiological evidence[J].Lancet,2019,394(10204):1159-1168.DOI:10.1016/S0140-6736(19)31709-X.
[18] de Villiers TJ,Hall JE,Pinkerton JV,et al.Revised global consensus statement on menopausal hormone therapy[J].Maturitas,2016,91:153-155.DOI:10.1016/j.maturitas.2016.06.001.
[19] Kotsopoulos J,Gronwald J,Karlan BY,et al.Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers[J].JAMA Oncol,2018,4(8):1059-1065.DOI:10.1001/jamaoncol.2018.0211.
[20] Stute P,Wildt L,Neulen J.The impact of micronized progesterone on breast cancer risk:a systematic review[J].Climacteric,2018(2):111-122.DOI:10.1080/13697137.2017.1421925.